понедельник, 13 февраля 2017 г.

Will Seattle Genetics' Deal With Immunomedics Get Scuttled?

Will Seattle Genetics' Deal With Immunomedics Get Scuttled?


The deal could be a big win for Seattle Genetics, but it doesn't have the full support of all of Immunomedics investors. After the closing market bell on Friday, venBio Select Advisors, LLC -- the beneficial owner of 9.9% of Immunomedics shares -- said Immunomedics' board of directors is "giving away its crown jewel."



from Biotech News